AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

Techcyte is proud to share results from a published pilot study demonstrating the effectiveness of its AI-powered kidney ...

Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...